期刊
JOURNAL OF NEUROTRAUMA
卷 33, 期 2, 页码 194-202出版社
MARY ANN LIEBERT, INC
DOI: 10.1089/neu.2015.3904
关键词
behavioral outcomes; CCI; methylene blue; mitochondria; MRI; TBI
资金
- National Institutes of Health/National Institute of Neurological Disorders and Stroke [R01 NS45879]
- Clinical Translational Science Awards (CTSA) [TL1, KL2, 8UL1TR000149, TL1TR001119, TR001118]
- Mike Hogg Fund
Traumatic brain injury (TBI) remains a primary cause of death and disability in both civilian and military populations worldwide. There is a critical need for the development of neuroprotective agents that can circumvent damage and provide functional recovery. We previously showed that methylene blue (MB), a U.S. Food and Drug Administration-grandfathered drug with energy-enhancing and antioxidant properties, given 1 and 3h post-TBI, had neuroprotective effects in rats. This study aimed to further investigate the neuroprotection of delayed MB treatment (24h postinjury) post-TBI as measured by lesion volume and functional outcomes. Comparisons were made with vehicle and acute MB treatment. Multi-modal magnetic resonance imaging and behavioral studies were performed at 1 and 3h and 2, 7, and 14 days after an impact to the primary forelimb somatosensory cortex. We found that delaying MB treatment 24h postinjury still minimized lesion volume and functional deficits, compared to vehicle-treated animals. The data further support the potential for MB as a neuroprotective treatment, especially when medical teatment is not readily available. MB has an excellent safety profile and is clinically approved for other indications. MB clinical trials on TBI can thus be readily explored.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据